Another Alzheimer’s Drug Candidate Bites the Dust
Add Baxter International’s Gammagard to the ash heap of failed Alzheimer’s drug candidates. Baxter announced today that Gammagard did not provide any cognitive or functional improvement in 390 patients with mild to moderate Alzheimer’s disease. The patients who were enrolled in the Phase III trial received the drug through infusions over an 18 month period.… Read More »